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ABSTRACT 
Recently, several studies have been reported that nonsteroidal anti-inflammatory drugs can fight against neurodegenerative disorders by various 
mechanisms. Currently, available therapies of neurodegenerative disorders (NDs) provide only symptomatic relief. This is the point at which we 
need an alternative that acts on the root cause of disease. Parkinson’s disease and Alzheimer’s disease are the two NDs concentrated here. Since the 
drug profile is already known, drug repurposing is a promising technique in research, thereby reducing the cost and period effectively. 
Epidemiological studies on various nonsteroidal anti-inflammatory drugs (NSAIDs) showed good results, but when it came to clinical studies the 
results are found to be poor. Hence, it can be concluded that NSAIDs provide its neuroprotective activity on its long-term use only, as the brain 
accessibility of this kind of drug is poor due to its lower lipophilicity.  
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INTRODUCTION 
Neuroprotection is referred to as approaches and correlated 
mechanisms that protect our central nervous system from neuronal 
injuries because of chronic or acute neurodegenerative disorders 
(NDs). The incidences of NDs are a result of deterioration and 
breakdown of neurons that finally leads to a cognitive and 
behavioral imbalance in patients. 
The symptoms of NDs include memory loss, learning difficulties, 
motor coordination, and other functional losses. Hypertension, other 
infections, environmental and genetic factors are the reasons 
underlying the disease. Other than these reasons, aging assumes a 
significant part in the rate of illness. The pathology associated with 
NDs includes the aggregation of proteins, inflammation, oxidative 
stress [1], and loss of neurotransmitters [2, 3]. Since the available 
treatments like Rivastigmine, Galantamine, Donepezil, Memantine, 
Memantine combined with Tacrine, and Donepezil are coming under 
supportive therapy regulating the levels of neurotransmitters, there 
is a great need for a new derivative for the root cause of the disease 
[2, 4]. 
Recent studies on NSAIDs have been proven that they can extent 
neuronal inflammation associated with the pathophysiology of 
neurodegenerative disorders. Epidemiological as well as 
immunochemical studies, suggested that individuals on long term 
anti-inflammatory drug treatment will reduce the risk of occurrence 
of NDs in elderly persons [5]. 
Since NSAIDs are widely used over the counter medication and the 
drug profile is already well known, drug repurposing is a promising 
method for the treatment of NDs. For further clarification on this 
review, we are correlating published data regarding NSAIDs as well 
as Alzheimer’s and Parkinson's disease. 
Search criteria 
This review included articles from 1990 to 2020 that were found in 
various electronic databases PubMed, Science Direct, Scopus, Web of 
Science, and Google Scholar by using the search words: 
neurodegenerative diseases, neuroprotection, antioxidant, 
Alzheimer’s disease, Parkinson Disease, Amyotrophic Lateral 
Sclerosis, Prion Diseases, Huntington Disease, mechanism of 
neurodegenerative disorders, NSAIDs, various NSAIDs used for the 
treatment of Alzheimer’s disease. 
Neurodegenerative disorders 
The major cause of the neurodegenerative disorder (ND) is neuronal 
cell death, particularly in the area of the CNS. Alzheimer's disease 
(AD), Parkinson's disease (PD), Multiple sclerosis (MS), Lewy body 
dementia (LBD), amyotrophic lateral sclerosis (ALS), Spongiform 
encephalopathy (Prion disease), and Huntington’s disease are such 
NDs [6]. Among these, Alzheimer's disease is the most prevalent one, 
followed by Parkinson's disease. NDs mainly affects the behavioral 
and cognitive functions of the patient. In all of these conditions, age 
plays a major role. Therefore, we can say that age is a risk factor for 
these types of diseases. The pathophysiology includes protein 
aggregation, inflammation, oxidative stress, and neurotoxicity [3, 7]. 
Alzheimer's disease (AD) 
Alzheimer's is a cumulative degenerative malady with early signs of 
forgetting recent events or conversations [8]. Progressively, the 
patient develops serious memory loss and incapability to run day-to-
day tasks. The available treatments for AD may only temporarily mask 
the symptoms and occasionally boost function and maintain 
independence for a time. Currently, no treatments offer a complete 
cure for this disease [4]. Difficulties from acute loss of brain function 
like dehydration, malnutrition, or infection are seen in the final stages 
of the disease, which will ultimately lead to death. It is believed that an 
association of genetic, lifestyle and environmental factors are the 
reasons behind AD. The precise reason for AD is still inconclusive, but 
a vital role is played by brain proteins that have lost their normal 
functioning, thereby disturbing neurons, and as a result, a series of 
toxic events occur. The symptoms will appear only after years when 
the damage occurs in the area that controls memory [9]. The loss of 
neurons extends predictably to other regions of the brain. The brain 
eventually gets shrunk in the late stages of the disease [3, 10].  
Two proteins that play a major role in AD 
Plaques: Plaques are dense insoluble leftover fragments of a larger 
protein called beta-amyloid, which is pruned from amyloid 
precursor protein (APP), having a toxic effect on other neurons and 
disturb cell to cell communication. 
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Tangles: Nutrients and other essential materials are transported by 
tau proteins and also act as internal support to neurons. In 
Alzheimer's disease, the transport system is disturbed by 
neurofibrillary tangles, which are formed as a result of structural 
changes and the organization of tau proteins [7, 11]. 
Parkinson disease (PD) 
PD is yet another incurable cumulative neurodegenerative disorder 
characterized by both motor and nonmotor symptoms like 
Alzheimer’s disease [12, 13]. Like AD the etiology of PD is also 
unknown, and it is believed that age, genetic and environmental 
factors are the reasons underlying the disease. The motor features 
include loss of striatal dopaminergic neurons and the nonmotor 
symptoms are responsible for the neuronal loss in nondopaminergic 
areas [12, 14]. Inflammation, oxidative stress, excitotoxicity, and 
reduced protein degradation, with mitochondrial dysfunction at the 
core, are the underlying mechanism of neurodegeneration [15]. As 
inflammation and oxidative stress add to the pathogenesis of PD, 
NSAIDs can beat against the root cause of disease as the currently 
available treatments only provide symptomatic relief [12]. 
Amyotrophic lateral sclerosis (ALS) 
ALS is also another progressive disorder marked by the 
degeneration of upper and lower motor neurons in the brain and 
spinal cord that supply voluntary neurons. The medulla and anterior 
horn of the spinal cord were affected in the case of lower motor 
neurons while in the case of the upper motor neuron, the cerebral 
cortex. Patients suffering from ALS undergo progressive muscle 
weakness and finally end up with death, usually due to respiratory 
failure [16]. The word 'Amyotrophy' indicates the atrophy of muscle 
fibers as the anterior horn cells degenerate the muscle fibers that 
then get denervated, which finally leads to weakness of affected 
muscles and visible fasciculations, while 'Lateral sclerosis' is the 
hardening of anterior and lateral corticospinal tracts as motor 
neurons degenerate and are replaced by gliosis [17]. 
Prion diseases 
Prion disease can be defined as a set of neurodegenerative diseases 
caused by abnormally shaped proteins called prions, that occur in 
sporadic (Jakob-Creutzfeldt disease), Gerstmann-Sträussler-
Scheinker syndrome, genetic (genetic Jakob-Creutzfeldt disease, and 
fatal familial insomnia), and acquired (kuru, variant Jakob-
Creutzfeldt disease, and iatrogenic Jakob-Creutzfeldt disease) forms, 
and the most common form that affects humans is Creutzfeldt-
Jakob disease (CJD)[18]. 
Huntington disease 
Huntington illness is a rare, incurable neurodegenerative disorder 
that affects the CNS. The symptoms include unwanted choreatic 
movements, dementia, behavioral and psychiatric disturbances. It is 
an autosomal dominant inherited disorder with continuous brain 
degeneration causing fast deterioration and eventually death. The 
most common cause of death is pneumonia, followed by suicide. The 
major population that is affected by the disease is the age group of 
30-50 y [19]. 
Mechanism of neurological diseases 
In all cases of neurodegenerative disorders, neuroinflammation is 
the underlying reason [20]. Some cerebral MR anomalies can be seen 
in patients suffering from neurodegenerative disorders. As a result 
of neuroinflammation, the immune cells in the circulatory system 
take up the central nervous system (CNS) and may constitute 
evidence for neural parenchymal damage. Also, the accumulated 
microglia surrounding the plaques, a local cytokine-mediated acute-
phase reaction, and initiation of the complement cascade are 
contributed to neuropathological characteristics. These pathological 
hallmarks may harm the neurons and the inflammatory responses 
can be inhibited by NSAIDs, which can regulate the levels of COX-1 
and COX-2 by triggering Peroxisome proliferator-activated receptor 
gamma (PPARγ) [21]. As this inevitable relationship between 
neuroinflammation and neurodegenerative disorder is well-
established, [22] NSAIDs can be recommended for NDs [20]. The 
level of cyclooxygenase enzymes like COX-1 and COX-2 will be high 
in conditions like neurodegenerative diseases, traumatic brain 
injury, and ischemic diseases [23]. The inflammatory cytokines get 
elevated and thereby, the PGE level also increased along with the 
induction of COX-2 [20]. Moreover, in astrocytes, the pro-
inflammatory cytokines can induce the expression of nitric oxide 
synthase and the activity of COX-2 [24]. Along with 
neuroinflammation, oxidative stress also prompts 
neurodegeneration. Free oxygen radicals, and consequently 
oxidative stress, trigger an increase in neurodegeneration [25, 26]. 
NSAIDs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drugs 
that produces their activity by inhibiting prostanoids through 
inhibition of cyclo-oxygenase enzymes. For many years, it has been 
popularly used for the treatment of disease conditions such as fever, 
arthritis, to reduce pain, inflammation, and to prevent the formation 
of blood clots [27]. Since 1990, researches have been actively going 
on to establish the relationship between NSAIDs and neurological 
disorders [28]. The first hint that NSAIDs can reduce the chance of 
AD was made from the observation of patients who under the 
treatment of NSAIDs for rheumatoid arthritis had a serendipitous 
low incidence of dementia [29]. 
NSAIDs in the prevention and treatment of Alzheimer’s disease  
Indomethacin, a well-established NSAID with the ability to cross the 
blood-brain barrier, reported an acceptable result on 6 mo, double-
blind, placebo-controlled study. About 44 patients with probable AD 
and a Mini-Mental State Examination (MMSE) score of 16 or more 
were included in this study. Efficiency was measured by considering 
the changes in the cognitive status score during the 6 mo of 
treatment and it is mentioned that the major dropout is due to 
gastrointestinal irritability. This study concluded with the 100-150 
mg/d dose of Indomethacin exhibited neuroprotective activity in 
mild to moderate AD patients in comparison with placebo patients 
[8]. A double-blind, randomized placebo-controlled trial of 
indomethacin suggested that NSAIDs were not effective for the 
treatment of AD. 51 patients with mild to moderate AD were 
selected for this study in which 26 patients were administered with 
50 mg twice-daily dose of the drug [30]. 
Even though it is unclear whether COX-1, COX-2, or both produced 
the neuroprotective activity, but Nimesulide a preferential COX-2 
inhibitor, showed satisfactory results in a randomized pilot study. 
Studies were designed to measure both the effectiveness as well as 
the adverse events associated with the NSAID, Nimesulide, in AD 
patients. About 40 volunteers were subjected to a randomized pilot 
study by dividing them into two equal groups. The results were quite 
impressive on long term therapy and the adverse symptoms were 
found to be mild [31]. 
About 20 usually practicing NSAIDs were tested for the effects 
onamyloid beta-peptide 42(Aβ42) in cell culture, and some of them 
showed better activity by lowering the Aβ42. These categories of 
NSAIDs were tested on transgenic mice, and in the final results, 
Indomethacin, Diclofenac, Diflunisal, Flurbiprofen, Ibuprofen, 
Fenoprofen, Meclofenamic acid, and Sulindac which, reduces Aβ42 
levels in the brains of mice, while Nabumetone, Ketoprofen, Aspirin, 
and Naproxen, didn’t regulate Aβ42 levels. This study suggests that 
recommended doses of some NSAIDs can lower the level of Aβ42. A 
mismatch was also found between the results obtained from cell 
culture study and animal study. This study also discussed the 
activity of R and S enantiomers of Flurbiprofen-they acted similarly 
against Aβ42, could target γ-secretase complex, and the nuclear 
factor kappa B (NF-κB) [32]. 
Mefenamic acid, an anthranilic acid derivative and a frequently 
prescribed NSAID, was found that it could diminish neuronal cell 
death prompt by Aβ1–42 treatment. And also, Mefenamic acid was 
found to exhibits the ability to trim down reactive oxygen species 
(ROS) and nitric oxide accumulation. The therapeutic potential as 
well as the neuroprotective mechanism of Mefenamic acid, were 
established by conducting in vitro and in vivo studies. The in vitro 
study suggested that as a result of the inhibitory activity on ROS 
(reactive oxygen species) and nitric oxide accumulation, the 
Mefenamic acid can act against Aβ1-42treatment or Swedish double 
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mutation of amyloid precursor protein (Swe-APP) orthe C-terminal 
fragments of APP (APP-CTs) expression by obstructing the 
cytochrome c release from mitochondria and also the caspase-3 
stimulation. Adding up to this, cell survival is accelerated by the up 
regulation of the anti-apoptotic protein Bel-XL expression. Through 
the in vivo study on Aβ1-42 pervaded Alzheimer’s disease rat model, it 
is revealed that Mefenamic acid can improve cognitive function [33]. 
A 52 w, multicentre, randomized, double-blind, placebo-controlled, 
parallel-group study of a selective COX-2 inhibitor, Celecoxib, were 
carried out on patients with mild to moderate AD to determine 
whether the drug possesses any neuroprotective activity. This study 
is concluded that a 200 mg bid celecoxib could not contribute to any 
improvement in patients and it was also observed that adverse 
events like death happened during this study, as the selected 
population was elderly with other comorbidities that affected the 
result [34]. Even so, Celecoxib also showed some successful 
outcomes inan18-month randomized, double-blind, placebo-
controlled, parallel-group trial. A daily dose of either 200 or 400 mg 
was given to a population of 40-80 y age group with mild self-
reported memory complaints. During the study, the participants 
experienced adverse events like gastrointestinal side effects. Despite 
these adverse effects the daily use of Celecoxib ameliorates cognitive 
functioning [35] and improves the prefrontal regional glucose 
metabolism. The study concluded that NSAIDs may have the ability 
to improve the cognitive functions in people with somewhat mild 
age-related cognitive complaints possibly before the neurological 
changes arise [36]. 
Ibuprofen, a propionic acid derivative, was analyzed for 
determination of the exact mechanism of action by usingisobaric 
tags for relative and absolute quantification (iTRAQ) coupled2-DLC-
MS/M Sanalysis and is the fundamental investigation of 
neuroblastoma cells where the S, as well as the R enantiomer of 
Ibuprofen, were tested in which the S enantiomer is come up with 
neuroprotective activity by regulating oxidative stress and by down 
regulating the Cyclophilin A (CYP-A) expression. On that account, the 
study suggests that via several cellular pathways, Ibuprofen can 
lessen the risk of AD [37]. Based on the epidemiological evidence, a 
12-month multicentre, randomized, double-blind, placebo-
controlled, parallel-group trial was carried out on 132 patients who 
were diagnosed with mild to moderate AD in the age group of 65 and 
above. About 400 mg Ibuprofen bds or placebo along with 20 mg od 
of Esomeprazole or placebo was administered in randomly 
distributed groups. Among this, 70% of both groups completed the 
study with identical Alzheimer's disease Assessment Scale-Cognitive 
Subscale (ADAS-cog) score worsening, indicating that either 
Ibuprofen is not effective in the tertiary precaution of mild to 
moderate AD or the 12-month study is not enough to prove the 
assumption [38]. A prophylactic treatment study of Ibuprofen on 
young triple transgenic (3XTg)-AD mice demonstrated a significant 
reduction of intraneuronal Aβ accumulation, improved cognitive 
performance, and also arrest the hyperphosphorylated tau 
immunoreactivity. Ibuprofen is administered as Ibuprofen 
supplemented chow to the 3XTg-AD mice, and the treated group has 
shown improved learning activity similar to the age-matched wild 
type. Simultaneously the untreated group came out with a 
remarkable disability to learn theMorris water maze (MWM) task. 
MWM is extremely reliant on hippocampal integrity and which is 
also considered as an estimate for the deficit in spatial reference and 
memory [39]. 
As per the previous reports, studies recommend that NSAIDs exert 
their neuroprotective activity by activated microglia and impaired 
Aβ accumulation especially the Aβ42 species in the brain. The 
Cardiovascular health cognition study was conducted on 3229, 65, 
and above aged community free of dementia at baseline using 
NSAIDs, Aspirin, and Acetaminophen. In which NSAID users 
exhibited a lowered probability of every kind of dementia especially 
associated with AD in individuals with one or moreapolipoprotein 
E(APOE ε4) alleles. At the same time NSAIDs who reported with Aβ42 
reduction, activity doesn’t show any superiority, while the 
Acetaminophen, as well as Aspirin, were not connected with any 
promising activity in this case [40]. 
Tarenflurbil, the R enantiomer of Flurbiprofen was previously 
reported as a selective Aβ42 reducing agent (SALA) that also 
regulates the γ-secretase activity. A phase Ⅱ, a multicentre, 
randomized, double-blind, placebo-controlled, parallel-group study 
carried out in a population of 210 patients with a mini-mental state 
examination score of 15-26. The 800 mg dose of Tarenflurbil twice 
daily for 24 mo was reported with fewer functional ability in 
comparison with placebo [41]. 
The protective effect of NSAIDs was investigated by examining 
several case studies obtained from the US Veteran Affairs Health 
Care System. The community aged 55 y and above with reported AD 
were considered in this study. The population who received NSAIDs 
for a long period was at a lower risk of AD. The protective effects of 
different NSAIDs seem to be different, in which Ibuprofen has shown 
promising results through Aβ42 regulation [42]. 
A recent study based on the hypothesis that NSAIDs can protect 
from AD incidence was manifested about a 71% reduction in the risk 
of death associated with AD in the aged population especially in 
Aspirin users [28]. 
A retrospective cohort study suggested that the frequency of 
incidence of AD is lowered in the case of Diclofenac when comparing 
to Naproxen and Etodolac. Diclofenac can actively transport across 
the blood-brain barrier (BBB) and activity is expected to be 
produced by lowering the level of amyloid-beta and interleukin 1 
beta [43]. 
CONCLUSION 
NSAIDs, the widely used Over the Counter medication, have been 
known for their neuroprotective activity for almost 30 y. From 1990-
2020 there were several types of research were happened via 
epidemiological study, clinical trials, experiments on transgenic mice 
as well as in vitro studies. The results were so confusing because 
several contradictions were observed even for the same drug on the 
final reports. The majority of researches are concluded with a 
hopeful result in the area of neuroprotective activity of NSAIDs by in 
vitro as well as in vivo studies. Simultaneously some mismatches 
were also reported with the in vitro and in vivo study of the same 
drug. NSAIDs produce its neuroprotective activity by a wide range of 
mechanisms such as reducing neuroinflammation by regulating 
various inflammatory pathways, regulating the level of Aβ and tau 
proteins, preventing the accumulation of reactive oxygen species, 
and nitric oxide. During the period of several studies, some of the 
volunteers were withdrawn from the clinical trials and some are 
died due to the adverse events associated with NSAIDs. 
In summary, the long-term treatment of NSAIDs only exhibited 
beneficiary activity against Alzheimer’s disease. The impaired 
activity is due to the limited brain accessibility because of low 
lipophilicity. Hence, we recommend, drug modification methods 
such as the pro-drug approach thereby we can improve the 
lipophilicity of the drug as well as balance the adverse events like 
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